Russia’s state nuclear corporation Rosatom said it has successfully tested facilities for the production of radiopharmaceuticals at a $300m nuclear research complex in Bolivia.
According to Rosatom, radiopharmaceuticals produced at the site will be used in more than 5,000 medical procedures a year in Bolivia. Radiopharmaceuticals, or medicinal radiocompounds, are a group of pharmaceutical drugs containing radioactive isotopes. They can be used as diagnostic and therapeutic agents.
According to Rosatom, radiopharmaceuticals produced at the site will be used in more than 5,000 medical procedures a year in Bolivia. Radiopharmaceuticals, or medicinal radiocompounds, are a group of pharmaceutical drugs containing radioactive isotopes. They can be used as diagnostic and therapeutic agents.
Rosatom said commissioning work is continuing at the facility, which will include a water-cooled research reactor with nominal power of up to 200 kW, an experimental gamma-installation, a cyclotron and radiopharmacology complex, engineering facilities and various laboratories.
In March 2016, Russia and Bolivia signed an agreement to cooperate on the construction of the centre at a site in the city of El Alto, western Bolivia.
In September 2017, the Bolivian Nuclear Energy Agency and JSC State Specialised Design Institute, a subsidiary of Russia’s state nuclear corporation Rosatom, signed a contract for construction.
